Rescripting Global Pharma Manufacturing Footprint – Regional Capacity Undoing Erstwhile Global Consolidation

Rescripting Global Pharma Manufacturing Footprint – Regional Capacity Undoing Erstwhile Global Consolidation

Tuesday, October 28, 2025 3:15 PM to 4:00 PM · 45 min. (Africa/Abidjan)
Hall 12.1 - 12.1C68
Future of Pharma & Ingredients
ManufacturingSupply ChainMarket Insights

Information

Rescripting Global Pharma Manufacturing Footprint

Quest for onshoring pharma manufacturing – Regional capacity undoing erstwhile global consolidation


COVID-19 laid bare vulnerability of global health systems as a result of highly consolidated global supply chain in pharmaceuticals. This stark realization triggered focus across regions on nurturing regional capacity in the interest of supply security. This is true of high income geographies such as Europe, America or the Middle East as well as Low and Middle Income Countries. While Governments and Global Health actors are championing regional manufacturing capacity with the objective of health security, industry is also keen to pursue expanded capacity across regions to de-risk supply chain vulnerability.


This undoing of global consolidation will have significant ramifications for the pharma industry. Historically consolidated global manufacturing landscape is unlikely to be the future of pharma. The panel will spotlight strategic perspective from across geographic regions and ideate implications. Industry leaders from key regional hubs and catalytic partners will reflect on momentum around regional capacity development and implications for future industry investments.

Siegfried AGSiegfried is a preferred partner for complete integrated Drug Substance and Drug Product services with production capabilities worldwide. Creating, improving and manufacturing formulations is our passion. Our professionalism is pivotal for your project throughout the entire life cycle. Our offering, the combination of inherited technical know-how and expertise, is unique for a supplier of development and manufacturing services. Our Drug Substance services include Custom Development and Contract Manufacturing for both APIs and intermediates. In addition, we offer a multiclient API portfolio (including controlled substances) with drug master files and patented technologies. Our Drug Product clients benefit from a broad spectrum of dosage forms and technologies like oral solids, inhalative products, opthalmics and sterile ointments. Drug Product services include Custom Development and Contract Manufacturing for the dosage forms mentioned above. Siegfried enhanced its Drug Product capabilities with the acquisition of two Novartis sites near Barcelona and the establishment of a center of excellence for developing and optimizing formulations. Thus, we expanded our competency with high potent Drug Product development and manufacturing down to an OEL of 1Mug/m3, next to capsules with APIs (down to 0.1 Mug/m3). Complex oral drug delivery systems or solubility increasing of APIs (e.g. nanomilling or spray drying) belong to our core competences. In the field of steriles, we are experienced with fill and finish of vaccines and biologic compounds. Furthermore, we can offer dry powder inhalator capsules. Siegfried has 11 GMP approved sites worldwide spanning both the eastern and western hemispheres. Our Drug Substance sites are located in Zofingen (Switzerland), Pennsville (US), Nantong (China), Minden (Germany), Evionnaz (Switzerland) and St. Vulbas (France). Our Drug Product locations are in H...

Registered attendees

AJ
Abhishek Jain
Global Director - Key Account Management - Health SectorDP World
AH
Agnieszka Han
Vice-CEOP.P.F. Hasco-Lek S.A.
Aidan Collins
Aidan Collins
Associate Director - Supply Chain, Technical OperationsPTC Therapeutics

Log in

See all the content and easy-to-use features by logging in or registering!